The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
NCCN Guidelines® Insights: Bladder Cancer, Version 2.2022: Featured Updates to the NCCN Guidelines
Open accessAbstract
The NCCN Guidelines for Bladder Cancer provide recommendations for the diagnosis, evaluation, treatment, and follow-up of patients with bladder cancer and other urinary tract cancers (upper tract tumors, urothelial carcinoma of the prostate, primary carcinoma of the urethra). These NCCN Guidelines Insights summarize the panel discussion behind recent important updates to the guidelines regarding the treatment of non–muscle-invasive bladder cancer, including how to treat in the event of a bacillus Calmette-Guérin (BCG) shortage; new roles for immune checkpoint inhibitors in non–muscle invasive, muscle-invasive, and metastatic bladder cancer; and the addition of antibody–drug conjugates for metastatic bladder cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(2017) · Springer eBooks · doi:10.1007/978-3-319-40618-3 · Cited by 17,242
Siegel, R. L., Miller, K. D., Fuchs, H. E., & Jemal, A. (2022) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21708 · Cited by 17,196
Rosenberg, J. E., Hoffman-Censits, J., Powles, T., van der Heijden, M. S., Balar, A. V., Necchi, A., Dawson, N., O'Donnell, P. H., Balmanoukian, A., Loriot, Y., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)00561-4 · Cited by 3,669
Self-citationPembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
Bellmunt, J., de Wit, R., Vaughn, D. J., Fradet, Y., Lee, J.-L., Fong, L., Vogelzang, N. J., Climent, M. A., Petrylak, D. P., Choueiri, T. K., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1613683 · Cited by 3,395
Sylvester, R. J., van der Meijden, A. P. M., Oosterlinck, W., Witjes, J. A., Bouffioux, C., Denis, L., Newling, D. W. W., & Kurth, K. (2006) · European Urology · doi:10.1016/j.eururo.2005.12.031 · Cited by 3,013
Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma
Powles, T., Park, S. H., Voog, E., Caserta, C., Valderrama, B. P., Gurney, H., Kalofonos, H., Radulović, S., Demey, W., Ullén, A., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2002788 · Cited by 1,493
Powles, T., Durán, I., van der Heijden, M. S., Loriot, Y., Vogelzang, N. J., De Giorgi, U., Oudard, S., Retz, M. M., Castellano, D., Bamias, A., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(17)33297-x · Cited by 1,408
Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma
Powles, T., Rosenberg, J. E., Sonpavde, G. P., Loriot, Y., Durán, I., Lee, J.-L., Matsubara, N., Vulsteke, C., Castellano, D., Wu, C., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2035807 · Cited by 1,229
Adjuvant Nivolumab versus Placebo in Muscle-Invasive Urothelial Carcinoma
Bajorin, D. F., Witjes, J. A., Gschwend, J. E., Schenker, M., Valderrama, B. P., Tomita, Y., Bamias, A., Lebret, T., Shariat, S. F., Park, S. H., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2034442 · Cited by 1,065
Powles, T., O'Donnell, P. H., Massard, C., Arkenau, H.-T., Friedlander, T. W., Hoimes, C. J., Lee, J. L., Ong, M., Sridhar, S. S., Vogelzang, N. J., et al. (2017) · JAMA Oncology · doi:10.1001/jamaoncol.2017.2411 · Cited by 869
Self-citationMassard, C., Gordon, M. S., Sharma, S., Rafii, S., Wainberg, Z. A., Luke, J., Curiel, T. J., Colon-Otero, G., Hamid, O., Sanborn, R. E., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.67.9761 · Cited by 840
Rosenberg, J. E., O’Donnell, P. H., Balar, A. V., McGregor, B. A., Heath, E. I., Yu, E. Y., Galsky, M. D., Hahn, N. M., Gartner, E. M., Pinelli, J. M., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.19.01140 · Cited by 642
BÖHLE, A., JOCHAM, D., & BOCK, P. R. (2003) · Journal of Urology · doi:10.1016/s0022-5347(05)64043-8 · Cited by 616
Balar, A. V., Kamat, A. M., Kulkarni, G. S., Uchio, E. M., Boormans, J. L., Roumiguié, M., Krieger, L. E. M., Singer, E. A., Bajorin, D. F., Grivas, P., et al. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00147-9 · Cited by 565
Tagawa, S. T., Balar, A. V., Petrylak, D. P., Kalebasty, A. R., Loriot, Y., Fléchon, A., Jain, R. K., Agarwal, N., Bupathi, M., Barthelemy, P., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.20.03489 · Cited by 543
Self-citationOddens, J., Brausi, M., Sylvester, R., Bono, A., van de Beek, C., van Andel, G., Gontero, P., Hoeltl, W., Turkeri, L., Marreaud, S., et al. (2013) · European Urology · doi:10.1016/j.eururo.2012.10.039 · Cited by 520
Powles, T., van der Heijden, M. S., Castellano, D., Galsky, M. D., Loriot, Y., Petrylak, D. P., Ogawa, O., Park, S. H., Lee, J.-L., De Giorgi, U., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30541-6 · Cited by 501
Self-citationFradet, Y., Bellmunt, J., Vaughn, D. J., Lee, J. L., Fong, L., Vogelzang, N. J., Climent, M. A., Petrylak, D. P., Choueiri, T. K., Necchi, A., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz127 · Cited by 480
SYLVESTER, R. J., van der MEIJDEN, A. P. M., WITJES, J. A., & KURTH, K. (2005) · Journal of Urology · doi:10.1097/01.ju.0000162059.64886.1c · Cited by 385
Shelley, M. D., Wilt, T. J., Court, J., Coles, B., Kynaston, H., & Mason, M. D. (2004) · BJU International · doi:10.1111/j.1464-410x.2003.04655.x · Cited by 342
Han, R. F., & Pan, J. G. (2006) · Urology · doi:10.1016/j.urology.2005.12.014 · Cited by 340
Rosenberg, J., Sridhar, S. S., Zhang, J., Smith, D., Ruether, D., Flaig, T. W., Baranda, J., Lang, J., Plimack, E. R., Sangha, R., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.02044 · Cited by 338
Self-citationPlimack, E. R., Bellmunt, J., Gupta, S., Berger, R., Chow, L. Q. M., Juco, J., Lunceford, J., Saraf, S., Perini, R. F., & O'Donnell, P. H. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30007-4 · Cited by 335
Self-citationShelley, M. D., Kynaston, H., Court, J., Wilt, T. J., Coles, B., Burgon, K., & Mason, M. D. (2001) · BJU International · doi:10.1046/j.1464-410x.2001.02306.x · Cited by 313
Yu, E. Y., Petrylak, D. P., O'Donnell, P. H., Lee, J.-L., van der Heijden, M. S., Loriot, Y., Stein, M. N., Necchi, A., Kojima, T., Harrison, M. R., et al. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00094-2 · Cited by 287
Di̇vri̇k, R. T., Yildirim, Ü., Zorlu, F., & Özen, H. (2006) · Journal of Urology · doi:10.1016/s0022-5347(05)01002-5 · Cited by 250
Joudi, F. N., Smith, B. J., & O’Donnell, M. A. (2006) · Urologic Oncology: Seminars and Original Investigations · doi:10.1016/j.urolonc.2005.11.026 · Cited by 245
MARTÍNEZ-PIÑEIRO, J. A., MARTÍNEZ-PIÑEIRO, L., SOLSONA, E., RODRÍGUEZ, R. H., FERNÁNDEZ GÓMEZ, J. M., MARTÍN, M. G., MOLINA, J. R., COLLADO, A. G., FLORES, N., ISORNA, S., et al. (2005) · Journal of Urology · doi:10.1097/01.ju.0000173919.28835.aa · Cited by 201
Chou, R., Selph, S., Buckley, D. I., Fu, R., Griffin, J. C., Grusing, S., & Gore, J. L. (2017) · Journal of Urology · doi:10.1016/j.juro.2016.12.090 · Cited by 186
Di Lorenzo, G., Perdonà, S., Damiano, R., Faiella, A., Cantiello, F., Pignata, S., Ascierto, P., Simeone, E., De Sio, M., & Autorino, R. (2010) · Cancer · doi:10.1002/cncr.24914 · Cited by 180
Huncharek, M. S., McGarry, R. C., & Kupelnick, B. (2001) · PubMed · Cited by 131
Catto, J. W. F., Gordon, K., Collinson, M., Poad, H., Twiddy, M., Johnson, M. I., Jain, S., Chahal, R., Simms, M. S., Dooldeniya, M., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.20.01665 · Cited by 123
Ritch, C. R., Velasquez, M. C., Kwon, D., Becerra, M. F., Soodana‐Prakash, N., Atluri, V. S., Almengo, K., Alameddine, M., Kineish, O., Kava, B., et al. (2019) · The Journal of Urology · doi:10.1097/ju.0000000000000593 · Cited by 114
Intravesical chemotherapy prophylaxis in primary superficial bladder cancer
Huncharek, M. S., Geschwind, J.-F. H., Witherspoon, B. J., McGarry, R. C., & Adcock, D. F. (2000) · Journal of Clinical Epidemiology · doi:10.1016/s0895-4356(99)00203-6 · Cited by 100
Klaassen, Z. W. A., Kamat, A. M., Kassouf, W., Gontero, P., Villavicencio, H., Joaquim Bellmunt, B., van Rhijn, B. W. G., Hartmann, A., Catto, J. W. F., & Kulkarni, G. S. (2018) · European Urology · doi:10.1016/j.eururo.2018.06.024 · Cited by 94
Intravesical gemcitabine for non-muscle invasive bladder cancer
Jones, G., Cleves, A., Wilt, T. J., MASON, M. D., Kynaston, H., & Shelley, M. D. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd009294.pub2 · Cited by 91
Mari, A., Kimura, S., Foerster, B., Abufaraj, M. M., D’Andrea, D., Hassler, M. R., Minervini, A., Morgan Rouprêt, A., Babjuk, M. M., & Shariat, S. F. (2018) · British Journal of Urology · doi:10.1111/bju.14417 · Cited by 84
Laukhtina, E., Abufaraj, M. M., Al-Ani, A. T., Ali, M. R., Mori, K., Moschini, M., Quhal, F., Motlagh, R. S., Pradère, B., Schuettfort, V. M., et al. (2021) · European Urology Focus · doi:10.1016/j.euf.2021.03.016 · Cited by 26
CIS of the Bladder: Significance and Implications for Therapy
Mirabal, J. L. R., Taylor, J. A., & Lerner, S. P. (2019) · Bladder Cancer · doi:10.3233/blc-190236 · Cited by 6
Cited by
Dyrskjøt, L., Hansel, D. E., Efstathiou, J. A., Knowles, M. A., Galsky, M. D., Teoh, J., & Theodorescu, D. (2023) · Nature Reviews Disease Primers · doi:10.1038/s41572-023-00468-9 · Cited by 544
Advances in diagnosis and treatment of bladder cancer
Lopez-Beltran, A., Cookson, M. S., Guercio, B. J., & Cheng, L. (2024) · BMJ · doi:10.1136/bmj-2023-076743 · Cited by 496
Metadata
- Authors
- Flaig, T. W., Spiess, P. E., Abern, M., Agarwal, N., Bangs, R., Boorjian, S. A., Buyyounouski, M. K., Chan, K., Chang, S., Friedlander, T., Greenberg, R. E., Guru, K. A., Herr, H. W., Hoffman-Censits, J., Kishan, A., Kundu, S., Lele, S. M., Mamtani, R., Margulis, V., Mian, O. Y., Michalski, J., Montgomery, J. S., Nandagopal, L., Pagliaro, L. C., Parikh, M., Patterson, A., Plimack, E. R., Pohar, K. S., Preston, M. A., Richards, K., Sexton, W. J., Siefker-Radtke, A. O., Tollefson, M., Tward, J., Wright, J. L., Dwyer, M. A., Cassara, C. J., & Gurski, L. A.
- Venue
- Journal of the National Comprehensive Cancer Network
- Publisher
- Harborside Press, LLC
- Published
- 2022-08
- Volume
- 20
- Issue
- 8
- Pages
- 866-878
- ISSN
- 1540-1405 (ISSN-L)
- 1540-1413
- OpenAlex
- W4290958800
- Cited by
- 296
- References
- 39
- FWCI
- 57.65
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.